A federal court ruled in Mylan's favor, finding no infringement of Novo's patent tied to Wegovy, rejecting direct, ...

After inking a related patent settlement last year, Viatris has cleared another obstacle in its quest to launch generic ...

Mylan shares were up more than 12 percent, at $20.78. Follow Michael J. de la Merced and Katie Thomas on Twitter: @m_delamerced and @katie_thomas.

Mylan, the profiteering, tax-dodging drug company currently taking immense heat for jacking up the price of its Epipen by 500%, announced Thursday that it will help more patients cover their ...

A former information technology executive at Mylan pleaded guilty on Friday to insider trading for using tips from the drugmaker's chief information officer to trade in its stock, generating $4.27 ...

Mylan's generic version will hit shelves within several weeks at a list price of $300 for a two-pack carton in dosages of either 0.15 milligrams or 0.30 mg, the company said.

Mylan NV said on Thursday it would reduce the out-of-pocket costs of its emergency EpiPen allergy injection for some patients amid a wave of criticism from lawmakers and the public over the ...

Mylan Inc. CEO Heather Bresch testifies during a hearing before the House Oversight and Government...[+] Reform Committee September 21, 2016 on Capitol Hill in Washington, D.C. (Photo by Alex Wong ...

Mylan has announced that US regulators are going to reject its generic version of GlaxoSmithKline’s asthma/COPD inhaler Advair Diskus. The firm revealed that it has received an update from the US Food ...